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Summary
The BCR/ABL1 fusion gene, usually carried by the Philadelphia chromo-
some (Ph) resulting from t(9;22)(q34;q11) or variants, is pathognomonic
for chronic myeloid leukaemia (CML). It is also occasionally found in
acute lymphoblastic leukaemia (ALL) mostly in adults and rarely in de novo
acute myeloid leukaemia (AML). Array Comparative Genomic Hybridiza-
tion (aCGH) was used to study six Ph(+)AML, three bi-lineage and four
Ph(+)ALL searching for specific genomic profiles. Surprisingly, loss of the
IKZF1 and/or CDKN2A genes, the hallmark of Ph(+)ALL, were recurrent
findings in Ph(+)AML and accompanied cryptic deletions within the
immunoglobulin and T cell receptor genes. The latter two losses have been
shown to be part of ‘hot spot’ genome imbalances associated with BCR/
ABL1 positive pre-B lymphoid phenotype in CML and Ph(+)ALL. We
applied Significance Analysis of Microarrays (SAM) to data from the ‘hot
spot’ regions to the Ph(+)AML and a further 40 BCR/ABL1(+) samples
looking for differentiating features. After exclusion of the most dominant
markers, SAM identified aberrations unique to de novo Ph(+)AML that
involved relevant genes. While the biological and clinical significance of this
specific genome signature remains to be uncovered, the unique loss within
the immunoglobulin genes provides a simple test to enable the differentia-
tion of clinically similar de novo Ph(+) AML and myeloid blast crisis of
CML.
Keywords: philadelphia chromosome, acute myeloid leukaemia, blast crisis
chronic myeloid leukaemia, genomic arrays, immunoglobulin gene loss.
The t(9;22)(q34;q11) or its variants result in the formation of
the Philadelphia (Ph) chromosome and the chimeric BCR/
ABL1 fusion gene, encoding a constitutively active tyrosine
kinase with oncogenic properties. While this chromosome
anomaly is pathognomonic for CML, it is also found in pre-
cursor B acute lymphoblastic leukaemia, Ph(+) ALL, especially
in adults. Less than 1% of newly diagnosed adults with acute
myeloid leukaemia (AML) have the Ph chromosome, Ph(+)
AML (Soupir et al, 2007) and when a proliferation of BCR/
ABL1 positive blasts is found on presentation, the distinction
between CML blast crisis (CML/BC), AML, ALL or bi-lineage
acute leukaemia (Bi-AL) may be not clear. Although some fea-
tures of the bone marrow morphology, immunophenotype
and BCR/ABL1 molecular transcript may suggest a diagnosis,
ultimately the distinction between Ph(+)AML and CML pre-
senting in acute phase may be whether chronic phase CML
develops after therapy. Indeed, BCR/ABL1(+) AML is not
included in the World Health Organization classification
(Swerdlow et al, 2008) as a distinct entity, mostly due to lack
of firm criteria to distinguish it from CML myeloid blast crisis
(CML/BCM) at presentation.
In a recent multi-institutional retrospective analysis of 16
cases with de novo Ph(+) AML, it was shown that the
patients share many clinical, pathological, and genetic fea-
tures with CML/BCM (Soupir et al, 2007). It appeared that
Ph(+) AML presented less often with splenomegaly, lacked
significant blood or marrow basophilia, and had a lower
bone marrow myeloid/erythroid ratio. Major additional cyto-
genetic features characteristic of CML were shown to be less
common in Ph(+) AML and response to tyrosine kinase
inhibitor (Imatinib) treatment was of limited duration.
Nevertheless the authors were unclear whether the clinical,
pathological, and cytogenetic differences found between
Ph(+) AML and CML/BCM represent true entity-defining
characteristics or merely differences reflecting a more rapid
clinical presentation of the same disease.
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The advent of array comparative genomic hybridization
(aCGH) opened a new possibility to screen an entire genome
for cryptic imbalances that may lead to gene dysfunction in
cancer cells. This proved to be the case for many haemato-
logical disorders including Ph(+)ALL and CML, where dele-
tions of CDNK1A/B (p16) and/or IKZF1 (Ikaros) were shown
to be unique recurrent features (Mullighan et al, 2007;
Usvasalo et al, 2008; Matteucci et al, 2010; Nacheva et al,
2010). Here we present a comparative study of 13 samples
classified as Ph(+)AML, Ph(+)ALL or Ph(+)Bi-AL leukaemia
along with 40 previously analysed samples of Ph(+) ALL,
CML chronic and blast phase as well as 10 disease-free con-
trols using high resolution aCGH analysis, posing the ques-
tion: does Ph(+) AML carry unique, entity defining genome
imbalances? We set out to search for genomic features that
differentiate clinically similar BCR/ABL1 positive presenta-
tions, the optimal treatments for which are very different
even in the era of tyrosine kinase inhibitors (Vardiman,
2009).
Materials and methods
Samples
We studied bone marrow (BM) and/or peripheral blood
presentation samples from nine adults with Ph positive
acute leukaemia enrolled into the Medical Research Council
(MRC) UK AML Trials 10, 11, 12 and 15. The selection
criterion for this study was availability of good quality total
genomic DNA. Six samples were identified as being of mye-
loid origin (five undifferentiated and one differentiated
type) and three were classified as Bi-AL. The laboratory and
clinical features are outlined in Table I. All samples were
centrally reviewed by the MRC haematologist using May-
Gr€unwald staining, immuno-cytochemistry and immuno-
phenotyping data when available. None of the patients were
treated with tyrosine kinase inhibitors, because they were
not part of the MRC treatment protocols for AML. Six
patients (Cases 1–6) failed to respond to treatment, includ-
ing bone marrow transplantation and their overall survival
(OS) ranged from 115 to 323 days (Table I). The OS of the
remaining three patients (Cases 7–9) ranged between 38
and 51 years (Table I).
Four Ph(+) samples from the MRC UK ALL12R Trial of
pre-B cell origin (CD19+, CD22+) were included in the study
as representative of BCR/ABL1(+)ALL genomes.
Techniques
The presence of the Ph chromosome and resulting BCR/
ABL1 fusion was identified by conventional karyotyping, flu-
orescence in situ hybridization (FISH) and real time poly-
merase chain reaction (qPCR) as previously described
(Nacheva et al, 2010). The immunoglobulin heavy chain
(IGH) and T cell receptor (TRG@) sequencing analyses were
carried out following routine protocols (Rai et al, 2010).
Genome investigation was conducted in several steps using
standard and customized oligonucleotide array platforms
(Agilent Technologies UK Limited, Stockport, Cheshire, UK).
Firstly, whole genome screening of all samples was performed
at uniform resolution by standard 244 K and 1 M array
(Agilent Design ID 014693 and 021529) as described previ-
ously (Nacheva et al, 2010). The Ph(+)ALL cases were only
analysed by 244 K array due insufficient material. In brief,
the arrays were hybridized following the manufacturer’s pro-
tocol. 500 ng of genomic test DNA was extracted from either
peripheral blood or BM samples. Commercially obtained
pooled normal DNA (Promega, UK, Southampton, UK) was
used as reference. The arrays were scanned and features
extracted using an Agilent DNA Microarray Scanner with
Control Software (Agilent, version 9.5). Agilent Genomic
Workbench software version 5 (ADM2, threshold 6.0) was
used to visualize, detect and analyse aberration patterns from
aCGH microarray profiles.
Table I. Clinical data for adults with BCR/ABL1 positive acute myeloid and biphenotypic leukaemia
Patient Age (years) Sex WBC 9 109/l FAB type
WHO
performance status CR date
Remission
days
Relapse
date
OS
days/years
1 44 M 8159 AML Diff. 2 02/03/1994 80 20/05/1994 115
2 75 F 14069 AML Undiff. 1 14/06/1996 45 29/07/1996 133
3* 28 F 7829 AML Undiff. 4 Resistant* disease 0 Resistant disease 227
4 35 F 3019 AML Undiff. 1 11/08/1998 83 02/11/1998 214
5 58 F 17400 AML Undiff. 0 02/09/1998 93 04/12/1998 153
6 36 F 10389 Bi-lineage AL 1 11/03/2004 245 11/11/2004 323
7 55 M 8519 AML Undiff. 3 NA NA NA 43
8 52 F 6329 Bi-lineage AL 0 NA NA NA 38
9 26 F 6109 Bi-lineage AL 0 NA NA NA 51
NA, not available; WBC, white blood cell count; FAB, French-American-British classification; WHO, World Health Organization; CR, complete
remission; OS, overall survival; M, male; F, female; AML, Acute Myeloid Leukaemia; Diff, differentiated; Undiff, undifferentiated; AL, acute
leukaemia.
*Matched unrelated donor bone marrow transplant on 13/12/1998.
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Next, aCGH was carried out on six Ph(+)AML samples
(Cases 1–5 & 7) and one Ph(+) bi-AL sample (Case 8) using
custom 15 K oligonucleotide arrays (Agilent, Design ID
0224931) that cover genome regions, aberrations of which
were shown by previous studies to be specifically associated
with lymphoid cell origin in BCR/ABl1 positive cells (Nacheva
et al, 2010). These results, together with data from 40 Ph(+)
samples from a previous study obtained under the same exper-
imental conditions, were explored for differentiating features
along with 10 samples from normal healthy donors as negative
controls. The 40 samples comprised of 10 Ph(+) B-ALL and 30
CML of which 10 were chronic phase, nine was myeloid, one
was mixed type and 10 were lymphoid blast crisis. The chro-
mosome profiles of the other Ph(+) cases matched the karyo-
type complexity of the Ph(+)AML samples (Table S1). The
MultiExperiment Viewer (MeV) implementation of Signifi-
cance Analysis of Microarrays (SAM) (Tusher et al, 2001) was
used as previously (Grace & Nacheva, 2012) to search the data
from the BCR/ABL1 positive genomes. Genome addresses are
given according to the genome build 36/hg18.
Results
The BCR/ABL1 fusion was found to result from the classical
t(9;22)(q34;q11) in all samples (Table II). Two of the Ph(+)
ALL cases had the p190 BCR/ABL1 fusion, all other samples
had the p210 type (Table II). The Ph chromosome was seen
as sole chromosome abnormality in two AML samples (Cases
1 and 4, Table II), the rest showed moderately complex
karyotypes with up to four additional numerical and/or struc-
tural chromosome aberrations. These involved the short arms
of chromosome 9 and 19, monosomy of 7, 9 and 22 or mar-
ker structures that remained unresolved by G banding. The
chromosome changes typical of CML blast phase (i.e. major
and minor route aberrations) were not seen in AML although
total aberration frequencies were similar (Table II, Table S1).
Array CGH screening using both standard 244 K and 1 M
platforms identified genome copy number aberrations (CNA)
in all Ph(+) positive samples (Table III). These varied in size,
location and recurrence, falling into two main categories: (i)
chromosomal/segmental CNA involving regions of 20 Mb or
more that can be detected but may not be resolved by con-
ventional karyotyping, and (ii) cryptic aberrations that are
beyond the resolution of the G banding analysis. All aberra-
tions additional to the t(9;22)9q34;q11) found by G banding
and FISH were also detected by genome array screening
(Table II, Molecular karyotypes in Fig 1 and Figs S1 & S2).
Whole chromosome aberrations are exemplified by mono-
somy 7 (Cases 6 and 8) and trisomy X (Case 7). Segmental
changes are exemplified by deletions at 9p13-p24 (Cases 3
and 7); cryptic loss at 9q34 consistent with deletions of der
(9)t(9;22) (Cases 6, 8 & 9) and gains of 9q34-qter & 22q11
indicative of double Ph chromosome (Case 1 and 2). In three
of the six karyotypically abnormal samples of this cohort
aCGH revealed an unexpected gain of the short arm of chro-
mosome 19, where both gains and losses were detected
Table II. Summary of G banding, FISH and molecular results for adults with BCR/ABL1 positive acute leukaemia.
Patient
Age (years)
Sex FAB type G banding karyotype
BCR/ABL1
FISH pattern
BCR/ABL1
fusion type
1 44 M AML 46,XY,t(9;22)(q34;q11)[20] 2F1R1G p210
2 75 F AML 46,XX,t(9;22)(q34;q11), -18, idic(Ph),
+mar[15]/47, idem,+idic(Ph)[5]
3F1R1G/4F1R1G p210
3 28 F AML 46,XX,t(9;22)(q34;q11)[1]/45,XX, der(9)t(9;22),
dic(9;20)(p1?3;p12), add(19)(p1?31),-22,
der(22)?t(19;22)(p?131;q11)[2]/44,idem, -9[17]
3F1R1G p210
4 35 F AML 46,XX,t(9;22)(q34;q11)[25] 2F1R1G p210
5 58 F AML 46,XX,t(9;22)(q34;q112),der(16)
t(1;16)(q23;q13)[15]/46,XX[15]
2F1R1G p210
6 36 F Bi-AL 45,XX,-7,t(9;22)(q34;q11)[18]/47,idem,+2mar[2] 1F1R1G p210
7 55 M AML 46,X,-Y,+X,add(3)(p11), der(9)del(9)(p12)
t(9;22)(q34;q11), der(22)t(9;22) [11]/46,XY[19]
2F1R1G p210
8 52 F Bi-AL 46,XX,t(9;22)(q34;q112)[1]/45, idem,-7[9] 1F1R1G p210
9 26 F Bi-AL 46,XX,t(9;22)(q34;q11)[20] 1F1R1G p210
10 43 M B/ALL 46,XY,t(9;22)(q34;q11)[20] 2F1R1G p210
11 17 M B/ALL 46,XY,t(9;22)(q34;q11)[20] 2F1R1G p210
12 50 M B/ALL 46,XY,t(9;22)(q34;q11)[18]/46,XY[2] 2F1R1G p190
13 52 M B/ALL 46,XY,t(9;22)(q34;q11)[20] 2F1R1G p190
FAB, French-American-British classification; FISH, fluorescence in situ hybridization; M, male; F, female; AML, Acute Myeloid Leukaemia; Bi-AL,
biphenotypic acute leukaemia; B/ALL, B cell acute lymphoblastic leukaemia; p210, major BCR breakpoint; p190, minor BCR breakpoint; BCR/
ABL1 D-FISH, dual fusion probe with 2F1R1G signal pattern indicative of BCR/ABL1 fusion, 3F1R1G/4F1R1G, extra BCR/ABL1 fusion(s),
1F1R1G, deletion der(9)t(9;22).
Does Ph(+)AML Exist?
ª 2013 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. 543
British Journal of Haematology, 2013, 161, 541–550
T
ab
le
II
I.
Su
m
m
ar
y
o
f
ge
n
o
m
e
ar
ra
y,
F
IS
H
,
q
P
C
R
an
d
se
q
u
en
ci
n
g
d
at
a
fo
r
ad
u
lt
s
w
it
h
B
C
R
/A
B
L
1
p
o
si
ti
ve
ac
u
te
le
u
ka
em
ia
.
P
at
ie
n
t
T
yp
e
aC
G
H
ID
T
o
ta
l
C
N
A
Se
gm
en
ta
l
C
N
A
C
ry
p
ti
c
C
N
A
G
ai
n
s
L
o
ss
es
IG
H
b
,
c
V
P
R
E
B
1
a
IG
L
L
1
T
R
G
@
/T
A
R
P
a
,
b
IK
Z
F
1
b
C
D
K
N
b
1
A
M
L
35
6*
(3
68
)
20
N
F
N
F
L
O
H
N
L
O
H
N
N
N
2
A
M
L
36
1*
(3
69
)
45
4p
16
,
7p
22
,
19
p
13
,
9q
34
/q
te
rb
,
22
p
/q
11
b
18
q
21
-2
3
L
O
H
N
L
O
H
N
N
N
3
A
M
L
31
9,
36
0*
(3
65
)
45
19
p
13
,
9q
34
/q
te
rb
,
22
p
/q
11
b
9p
12
/p
24
,
20
p
11
/p
13
L
O
H
L
O
H
N
L
O
H
L
O
H
L
O
H
4
A
M
L
31
5,
31
6*
(3
62
)
31
N
F
N
F
L
O
H
N
N
L
O
H
L
O
H
L
O
H
5
A
M
L
31
7*
(3
63
)
37
1q
21
/q
44
b
16
q
12
/q
24
L
O
H
N
N
L
O
H
L
O
H
N
6
B
i-
A
L
35
4,
35
9*
29
N
F
7p
/q
b
,
9q
34
.1
b
d
,
22
q
11
.1
b
d
L
O
H
N
N
L
O
H
L
O
H
N
7
A
M
L
35
3*
(3
67
)
53
X
p
/q
3p
11
/p
24
,
9p
13
/p
24
L
O
H
L
O
H
N
L
O
H
L
O
H
L
O
H
8
B
i-
A
L
35
2*
(3
66
)
44
N
F
7p
/q
b
,
9q
34
.1
b
d
,
22
q
11
.1
b
d
L
O
H
N
L
O
H
L
O
H
L
O
H
L
O
H
9
B
i-
A
L
35
5*
18
N
F
9q
34
.1
b
d
,
22
q
11
.1
b
d
N
N
L
O
H
N
N
N
10
B
-A
L
L
31
8
(3
64
)
22
N
F
N
F
L
O
H
N
N
L
O
H
N
N
11
B
-A
L
L
26
7
(2
97
)
10
6
N
F
N
F
N
H
Z
L
L
O
H
L
O
H
L
O
H
N
12
B
-A
L
L
26
8
(3
01
)
31
X
p
/q
b
N
F
L
O
H
N
N
L
O
H
L
O
H
N
13
B
-A
L
L
26
9
(3
05
)
9
N
F
N
F
L
O
H
N
N
L
O
H
N
N
Se
gm
en
ta
l
C
N
A
,
ab
er
ra
ti
o
n
s
in
vo
lv
in
g
re
gi
o
n
s
>
20
M
b
;
C
ry
p
ti
c
C
N
A
,
ab
er
ra
ti
o
n
s
sm
al
le
r
th
an
20
M
b
;
G
ai
n
s
an
d
L
o
ss
es
li
st
o
f
se
gm
en
ta
l
ch
an
ge
s;
IG
H
,
im
m
u
n
o
gl
o
b
u
li
n
h
ea
vy
ch
ai
n
;
V
P
R
E
B
1
&
IG
L
L
1,
li
gh
t
ch
ai
n
s;
T
A
R
P
,
T
ce
ll
re
ce
p
to
r
ga
m
m
a;
aC
G
H
ID
,
ar
ra
y
co
m
p
ar
at
iv
e
ge
n
o
m
ic
h
yb
ri
d
iz
at
io
n
id
en
ti
fi
ca
ti
o
n
n
u
m
b
er
,
d
en
o
te
s
an
al
ys
is
w
it
h
.
*1
M
an
d
n
u
m
b
er
in
b
ra
ck
et
s
-
w
it
h
cu
st
o
m
iz
ed
h
ig
h
re
so
lu
ti
o
n
(~
1
k)
o
li
go
n
u
cl
eo
ti
d
e
ar
ra
ys
(A
gi
le
n
t
cu
st
o
m
ar
ra
y
ID
02
15
29
);
T
o
ta
l
C
N
A
,
in
cl
u
d
es
b
o
th
co
p
y
n
u
m
b
er
va
ri
at
io
n
s
(C
N
V
)
an
d
ac
q
u
ir
ed
ab
er
ra
ti
o
n
s
(C
N
A
)
(d
et
ai
ls
in
su
p
p
le
m
en
ta
ry
d
at
a)
;
A
M
L
,
ac
u
te
m
ye
lo
id
le
u
ka
em
ia
,
B
i-
A
L
,
b
i-
p
h
en
o
ty
p
ic
ac
u
te
le
u
ka
em
ia
;
B
-A
L
L
,
ac
u
te
ly
m
p
h
o
b
la
st
ic
le
u
ka
em
ia
;
N
F
-
n
o
t
fo
u
n
d
;
X
p
/q
an
d
7p
/q
–
d
en
o
te
s
w
h
o
le
ch
ro
m
o
so
m
e
ch
an
ge
s;
L
O
H
,
lo
ss
o
f
h
et
er
o
zy
go
si
ty
;
H
Z
L
,b
i-
al
le
li
c
lo
ss
,
N
,
n
o
rm
al
.
a C
o
n
fi
rm
ed
b
y
re
al
ti
m
e
p
o
ly
m
er
as
e
ch
ai
n
re
ac
ti
o
n
(q
P
C
R
).
b
C
o
n
fi
rm
ed
b
y
fl
u
o
re
sc
en
ce
in
si
tu
h
yb
ri
d
iz
at
io
n
(F
IS
H
).
c C
o
n
fi
rm
ed
b
y
IG
H
/T
R
G
@
se
q
u
en
ci
n
g.
d
C
o
n
si
st
en
t
w
it
h
d
el
et
io
n
(d
er
)(
9)
t(
9;
22
).
E. P. Nacheva et al
544 ª 2013 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2013, 161, 541–550
(Figs S3a–c). The commonly affected sequences at 19p132
region house relevant genes such as zinc fingers (RNF126
and ZDHHC8), protein (MAP2K2 and PTPRS) and tyrosine
(TYK2) kinases.
Cryptic aberrations were revealed by aCGH in all Ph (+)
samples (Table III, see cytoreports in Fig 1 and Figs S1 &
S2). These varied both in size (from 1 Kb to 20 Mb) and in
number (from 9 to 106 per genome) (Table III) but lacked
any correlations with the chromosome complement. How-
ever, recurrent aberrations typically associated with Ph(+)
ALL, such as losses of the IKZF1 and CDKN2A gene regions
were seen in 4/6 of the Ph(+)AML samples and at similar
frequency in bi- AL (in 2/3). Another uniform feature pres-
ent in all Ph(+) samples was the concomitant loss within the
immunoglobulin (IGH) and T cell receptor (TRG@) gene
complexes, as seen previously in large cohort of CML/BCL
samples (Nacheva et al, 2010).
We endeavoured to search the genome array data for
differentiating aberrant patterns. Indeed, cryptic losses at
identical locations were apparent across the Ph(+) AML,
Bi-AL and ALL samples (Table III). These included the loss
of sequences involving the V3-6D1-26J4-6 regions from
chr14:105,334,536 to chr14:106,172,371 within IGH complex
at 14q3233, seen in all but one Bi-AL (case 9) and one
ALL (case 11). However, in the latter two samples deletions
were detected in the light chain IG immunoglobulin
regions (IGLL1) at 22q112 (Table III). These chromosome
14 deletions were accompanied by loss within the TRG@
alternate reading frame protein (TARP) at chr7:38,262,501-
38,349,233 sub-band 7p141 seen in 4/6 AML, 2/3 Bi-AL
and all four ALL samples (Figs 2-4, see molecular karyo-
types in Figs S1, S2 & S4). Copy number loss at 7p122
involving the IKZF1 gene was found in 4/6 AML, 2/4
Bi-AL and 2/4 ALL samples. Losses were also detected at
9p213 affecting CDKN2A/2B in 3/6 Ph(+)AML and 1/3
Bi-AL (Table III). Sequencing data of the IGH regions in
nine cases with Ph(+)ALL, Ph(+)AML and CML/BCL were
in agreement with the recurrent genome losses identified
(A) (B) (C)
(D) (E) (F)
Fig 1. Molecular karyotype of Ph(+) AML: cases 1–5 & 7. Diagrammatic presentation (Cyto report, Genomic Workbench, version 50, Agilent)
of the genome data for five Ph(+) acute myeloid leukaemia (AML) and one suspected AML samples (A–F, ID numbers as per Tables II & III)
with the corresponding G banding results. Bars on the right of each chromosome represent gains (in red) and losses (in green). Copy number
aberrations, variable in number and size are present in all samples. Common losses seen in all at 7p141 and 14q323 are indicated by green
arrow, while recurrent gains at 19p are marked by red arrow.
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by aCGH (Table S2). Also, deletions within the 22q112
region affecting sequences at two locations flanking the
BCR gene were found in AML (Cases 1 & 2), Bi-AL (Cases
8 & 9) and ALL (Case 11). Importantly, both these
sequences within 22q112 - VPREB1 located proximal to
BCR at chr22:20,929,200-20,929,926 and IGLL1 at
chr:22,245,313-495, some 255 kb distal to BCR, house the
pseudo light chain proteins required for the assembly of a
functional IGHl (Figs S5 & S6).
A set of non-randomly affected genome loci (‘hot spots’),
including sequences within the IGH and TRG@ gene regions
were identified in our previous aCGH study of a large
cohort of Ph(+) CML (Nacheva et al, 2010) and Ph(+) ALL
samples (Chanalaris et al, 2008). SAM showed that the loss
of these loci was restricted to Ph(+) cells with lymphoid
phenotype. We used the same custom arrays (Agilent
Design ID 0224031) consisting of 15 000 probes covering
the ‘hot spot’ areas at ~1K resolution to assess these geno-
mic regions in the Ph(+) AML samples. A total of 47 BCR/
ABL1 positive samples, comprising of six AML, 1 Bi-AL
and 10 each of ALL, CML chronic phase, myeloid, lym-
phoid and bi-phenotypic blast crisis (positive controls)
together with 10 samples from healthy individuals (negative
controls) were screened under the same conditions. Among
the top 100 most significant loci identified by SAM were
the IGH/V3-6D1-26J4-6 and the TRG@/TARP sequences. Sam-
ples with these losses formed a cluster of BCR/ABL1 posi-
tive acute leukaemia with lymphoid phenotype, as seen in
Fig 3 (areas in green to the left of the heat map). These
include all of the Ph(+)AML together with Ph(+)ALL and
CML in lymphoid blast transformation. Note that none of
the CML chronic phase, myeloid blast crisis or control sam-
ples showed this pattern of concomitant IGH/TRG@ gen-
ome loss (Fig 3 and 4).
Given that the losses within IGH and TRG@ are almost
universal for the Ph(+) cells of lymphoid origin, we applied
SAM to the target array data excluding these regions. Cluster
analysis of the top 39 genome loci significantly differentiated
a cluster of AML samples (Fig 5, Table S3). The most signifi-
cant genome loci included relevant genes - RNF38 at 9p132
(protein with a RING motif - a zinc binding domain, found
in a number of proteins with a role in diverse cellular pro-
cesses, including oncogenesis, development, signal transduc-
tion and apoptosis), NCS1 at 9q341 (neuronal calcium
Fig 2. Concomitant deletions at IGH/VDJ and TRG@ (TARP) regions in Ph(+) acute leukemia samples. Diagrams of chromosomes 7 and 14
(Genomic Workbench, Agilent) of Ph(+) AML and ALL samples (ID on the top) are shown with genome loss marked in green and gain - in red.
Losses at TRG@ (alternate reading frame protein, TARP) and IGH/VDJ gene regions are indicated by red arrows, while grey arrows show
deletions at IKZF1 and imbalances within the TCR alpha/delta and beta loci. Small black arrows at the bottom point at cases 355 and 361, who
carry deletions within IGLL1 region (Table II). Graphs on the right (Formatter) display FR values at 1Kb resolution (Agilent, custom arrays
ID 0224931), for TRG@ and IGHVDJ regions, in red are FR graph for cases 355 and 356.
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sensor 1), PPP1R12B (protein inhibitor) at 1q321, PTPRN2
(tyrosine phosphatase) at 7q363 and oncogene SEPT9 at
17q253 region. Also featured are probes from the regions of
19p13 (PPAN, ICAM1, CCDC94 and PDE4A) and 10q241
(CNNM2) (Table S3).
Discussion
Typically a multistage disorder, CML progresses from an ini-
tial indolent chronic phase to an accelerated phase and, if
untreated, to terminal blast crisis with either myeloid or less
frequently, lymphoid or mixed immuno-phenotype. Rarely,
CML patients may present in blast crisis without a history of
preceding chronic phase (Kantarjian et al, 2003). In such
cases it may be impossible to differentiate CML/BC from Ph
(+)ALL and/or de novo AML due to the lack of firm criteria
at the clinical, haematological and genetic level. Here we
report a high-resolution aCGH study of BCR/ABL1 positive
leukaemia where we identified recurrent genome features that
allow the distinction of Ph(+)AML from both CML BM and
from Ph(+)ALL. To date, we and others have shown that
adult Ph(+)ALL and lymphoid blast crisis of CML share
common genomic features, in particular, the recurrent but
not universal loss of the IKZF1 and CDNK1A/B genes
(Mullighan et al, 2007; Nacheva et al, 2010). In addition, our
Fig 4. Loss within IGH/VDJ region is restricted to BCR/ABL1 posi-
tive genomes of lymphoid origin. Average fluorescence ratio values
(FR, vertical axis) for each of the 20 probes (horizontal axis) cover-
ing the chr14: 105,405,050 - 105,415,455 (hg18) region from 10 Ph
(+) ALL and 10 CML/LBC (combined, graph in blue), 10 CML/MBC
(in green) and 6 Ph(+)AML (in red) plotted together demonstrate
the unique association of the IGH/VDJ loss with lymphoid BCR/
ABL1(+) genomes.
Fig 3. SAM analysis defines the concomitant loss of IGH/VDJ and TRG@ (TARP) sequences as significantly associated with lymphoid BCR/ABL1
positive genomes. Top 52 loci from the IGH/DJ and the TRG@ (TARP) regions, the loss of which is shown to be significantly associated lym-
phoid BCR/ABL1 (+) genomes (areas in green on the heat map) by SAM investigation of data from custom array (Agilent, custom array ID
0224931) of 47 Ph(+) samples. Red arrows show the six BCR/ABL1(+)AML, the blue arrow points to a bi-phenotypic AL, all of which are cluster-
ing with the ALL and CML lymphoid BC(L). Note that none of the remaining CML chronic phase (C), CML myeloid blast crisis (M), and 10
controls (ctrl) samples show the concomitant IGH/TRG@(TARP) loss.
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laboratory has a substantial collection of Ph(+) B-cell acute
leukaemia cases where aCGH identified recurrent concomi-
tant loss of specific sequences within the IGH and TRG@
regions (Chanalaris et al, 2008; Nacheva et al, 2010). Such
illegitimate non-productive IGH and TRG@ gene rearrange-
ments are known to occur in acute leukaemia of both lin-
eages and are used as markers for residual disease (van der
Velden et al, 2007). Indeed, cryptic deletions within the
immunoglobulin genes have been already linked to the mal-
function of the RAG1/RAG2 system due to elevated AID
expression in BCR/ABL1 positive acute leukaemia cells (Feld-
hahn et al, 2007).
The combined recurrent losses within the TRG@ and IGH
regions appear more common than deletions of IKZF1 - a
gene already closely identified with lymphoid disease. This
concomitant loss occurs at genome loci reported to have
imbalances in disease-free individuals, referred to as Copy
Number Variation (CNV) and considered to be polymorphic
markers. It is known that CNVs overlap some 7000 genes in
humans, many of them pivotal in pathological pathways
(Feuk et al, 2006). However, in contrast with a typical CNV
that could affect any part of the IGH gene, the deletions
identified here in the genome of BCR/ABL1 positive ALL and
AML (Table III, Fig 2-3) always involved exactly the same
sequences at chr14:105,405,050-105,415,455 and were accom-
panied almost universally by deletions of TRG@/TARP. Since
both IGH and TRG@ regions are usually excluded from
aCGH analysis such recurrent aberrations may be over-
looked. Additionally, deletions at 22q112 involving the
VPREB1 and IGLL1 sequences were found in two of the six
Ph(+)AML and one of each Bi-AL and ALL cases. Notably,
the losses of IGH, TRG@, VPREB1 and IGLL1 identified in
samples of de novo BCR/ABL1(+) AML, Ph(+)ALL and CML
lymphoid BC, and confirmed by both qPCR and sequencing,
were not detected either in any of the CML chronic phase or
myeloid blast crisis, nor in any of AML samples with normal
karyotype investigated under the same conditions (data not
shown). In these latter cases, both the IGH, TRG@/TARP
Fig 5. Genome differences in Ph(+)ALL and Ph(+)AML. Cluster analysis of probes (custom array data, Agilent, custom array ID 0224931) judged
to be significant for differentiating between Ph(+) ALL and AML in the absence of IGH and TRG@ (TARP) probes. Note that the AML samples
cluster together (red arrows) and six of the 10 ALL samples form a separate group (on the left of the heat map, blue arrows).
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and VPREB1/IGLL1 regions showed variations similar to
those reported in disease-free individuals (Chanalaris et al,
2009).
The recurrent ~10 Kb loss at chr14:105,405,050-
105,415,455, involves among others the IGHM(l) sequences,
which, when coupled to the surrogate two light chain com-
ponents VPREB1 and IGLL1, forms the pre-B cell receptor,
necessary for the normal B cell development (Nahar &
Muschen, 2009; Martensson et al, 2010). Productive rear-
rangement of the VH to DJH segments is a prerequisite for
the expression of the functional l chain and hence the tran-
sition from pro-B to pre-B cells stage. The possible role of a
tumour suppressor for the pre-B cell receptor was implicated
in B/ALL with and without a Ph(+) chromosome (Den Boer
et al, 2009) and in therapy-resistant CML (Nowak et al,
2010). The function of pro-B cell receptor signalling in 22
cases with Ph(+)ALL was shown to be associated with gen-
ome deletions in a set of pre-B cell receptor related genes
using the 250 SNP-chip platform (Trageser et al, 2009). The
high frequency of defects in the pre-B cell receptor can be
attributed to the increased genetic instability of BCR/ABL1
positive ALL, probably owing to the aberrant expression of
the mutator enzyme activation-induced deaminase (AID).
Indeed the study reported by Klemm et al, 2009) provided
multiple lines of evidence indicating AID both in generation
of point mutations and copy number aberrations in a num-
ber of genes that are involved in DNA repair, DNA damage
signalling or cell cycle control including immunoglobulin
genes. However it is currently unclear whether pre-B cell
functioning is required to enable malignant outgrowth in
ALL or function to suppress it (Nahar & Muschen, 2009;
Gruber et al, 2010).
Although the pathogenesis of the unique loss within the
immunoglobulin regions is far from clear, it has an impor-
tant practical benefit – a straightforward way to differentiate
two clinically and biologically similar conditions with differ-
ent treatment requirements – de novo acute myeloid leukae-
mia and blast phase of CML.
By removing the dominant IGH and TRG@ probes from
the high resolution data set, cluster analysis of SAM results
highlighted a further list of probes distributed across the gen-
ome that could discriminate the Ph(+)AML from any other
Ph(+) acute malignancy. The small data set limits the statisti-
cal significance of these results but differences in the genome
profile found cannot be attributed to karyotype features
because the chromosome complexity of the Ph (+)AML and
Ph(+)ALL samples interrogated by SAM have similar charac-
teristics (Table S1).
Our results show that Ph(+)AML possesses all the genome
characteristics of lymphoid disease: it shares well-
documented deletions of IKZF1 and CDNK1A/B as well as
the almost universal deletions of the TRG@ and IGH regions
shown by us to be specific markers for pre-B cell leukaemia.
However, Ph(+)AML does display some differences in the
presence of 19p chromosome gains and a unique genomic
profile calculated after exclusion of the more dominant
markers. These features, supporting the view that Ph(+)AML
represents a separate entity that may benefit from alternative
treatment protocols, require further investigation to elucidate
their biological and clinical significance. A step toward this
goal was provided just as this study was under review. In a
search for a molecular signature for Ph(+)AML, Konoplev
et al (2013) screened nine patients with de novo Ph(+)AML
and five with CML/BCM for mutations in 14 genes, two of
which, ABL1 and NPM1, showed recurrent changes. While
none of the nine Ph(+)AML patients showed ABL1 kinase
domain aberrations, two had typical NPM1 exon 12
mutations. In contrast, one of the five CML blast phase (BP)
samples had ABL1 mutations but none displayed NPM1
changes, thus suggesting that “Ph(+)AML is distinct from
CML/BP”. These data are consistent with our findings but
whereas the NPM1 gene mutation is a recurrent rather than
universal feature, the 100% loss of the immunoglobulin
sequences in Ph(+)AML offers a reliable test suitable for rou-
tine practice.
In summary, despite its clinical diversity, BCR/ABL1(+)
AML has a unique genome signature distinctly different from
both Ph(+)ALL and CML/BCM. It does exist.
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